Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20723435 | 0.98 | EPHX1 (0.45) | EPHX1TDP1POLBCA12CA1 | |
| SCHEMBL23373279 | 0.78 | TDP1 (0.37) | EPHX1TDP1ALOX15 | |
| SCHEMBL20739948 | 0.78 | TDP1 (0.37) | EPHX1TDP1ALOX15 | |
| SCHEMBL19206550 | 0.77 | KMT2A (0.43) | POLBRAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL20739923 | 0.75 | EPHX1 (0.36) | EPHX1TDP1CA12CA1CA2 | |
| SCHEMBL14260876 | 0.71 | MGAM (0.41) | EPHX1TDP1CA1CA2 | |
| SCHEMBL6232907 | 0.71 | MGAM (0.41) | EPHX1TDP1CA1CA2 | |
| SCHEMBL3340637 | 0.71 | MGAM (0.41) | EPHX1TDP1CA1CA2 | |
| SCHEMBL14394993 | 0.71 | MGAM (0.41) | EPHX1TDP1CA1CA2 | |
| SCHEMBL14367251 | 0.71 | MGAM (0.41) | EPHX1TDP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414249-B1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3414249-B1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3414249-A1 | PDE1 INHIBITOR | Eli Lilly and Company (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10112951-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180099973-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099973-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099973-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-04-12 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| WO-2017139186-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139186-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112951-B2 | PDE1 inhibitor | PDE3B, PDE5A, PDE3A | EPHX1 681/4885TDP1 696/4885POLB 4189/4885 |
| US-20180099973-A1 | PDE1 INHIBITOR | PDE3B, PDE5A, PDE3A | EPHX1 681/4885TDP1 696/4885POLB 4189/4885 |
| US-20170233396-A1 | PDE1 INHIBITOR | PDE3B, PDE5A, PDE3A | EPHX1 681/4885TDP1 696/4885POLB 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.